Update on Atopic Dermatitis Treatment Options and the Role of Biologics (AAN)
Price: FREE for members and non-members
Session recorded on September 18, 2024
Speaker: Peck Y. Ong, MD
Biologics are typically prescribed for people living with persistent, moderate-to-severe atopic dermatitis who need more than topical treatments. Biologic medications can reduce inflammation and calm the immune system in people living with atopic dermatitis. In this webinar, you will learn about the pathophysiology of atopic dermatitis, the current and upcoming treatments and the unmet needs in atopic dermatitis.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
Explore other archived clinical webinars here.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Allied Health Professionals
Learning Objectives
Upon completion of this activity learners should be able to:
1. Describe the pathophysiology of atopic dermatitis.
2. Summarize the current and upcoming treatments and the treatment targets for atopic dermatitis.
3. Specify the unmet needs in atopic dermatitis.
All identified relevant financial relationships with ineligible companies have been mitigated.
Speaker:
Peck Y. Ong, MD
Advisor: Dermavent, Amgen
Researcher: Regeneron, Sanofi
Moderator:
Catherine Blackwell, Allergy Asthma Network (AAN)
No identified relevant finanical relationships with ineligible companies to disclose
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance